Zura Bio (NASDAQ:ZURA) Stock Price Up 7.8% – Time to Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price was up 7.8% on Monday . The stock traded as high as $5.64 and last traded at $5.64. Approximately 40,095 shares were traded during trading, a decline of 95% from the average session volume of 839,422 shares. The stock had previously closed at $5.23.

Analyst Ratings Changes

Several research analysts have recently issued reports on ZURA shares. Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Zura Bio from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Finally, William Blair started coverage on Zura Bio in a report on Wednesday, July 8th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Trading Up 5.0%

The firm’s 50 day simple moving average is $4.55 and its 200-day simple moving average is $5.37. The company has a market capitalization of $520.89 million, a price-to-earnings ratio of -5.04 and a beta of -0.03.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, sell-side analysts forecast that Zura Bio Limited will post -0.76 EPS for the current fiscal year.

Institutional Trading of Zura Bio

Several hedge funds have recently modified their holdings of ZURA. Bank of America Corp DE boosted its stake in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares in the last quarter. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter worth $72,000. JPMorgan Chase & Co. lifted its holdings in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the period. Jane Street Group LLC acquired a new stake in Zura Bio in the second quarter valued at $113,000. Finally, UBS Group AG lifted its holdings in Zura Bio by 878.3% in the third quarter. UBS Group AG now owns 305,329 shares of the company’s stock valued at $1,322,000 after acquiring an additional 274,118 shares during the period. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.